PLCB2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10293(PLCB2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

Phospholipase C beta 2 (PLCB2) is a critical enzyme in intracellular signaling, primarily involved in hydrolyzing phosphatidylinositol 4.5-bisphosphate (PIP2) into secondary messengers inositol 1.4.5-trisphosphate (IP3) and diacylglycerol (DAG). These molecules regulate calcium release and protein kinase C activation, influencing processes like immune response, neurotransmission, and cell proliferation. PLCB2 is highly expressed in hematopoietic cells, particularly in B lymphocytes and platelets, and plays a role in B-cell receptor signaling and platelet activation.

PLCB2-specific antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry, and flow cytometry. Researchers employ them to investigate PLCB2's involvement in immune disorders (e.g., PLCB2 mutations linked to immunodeficiency), cancer (aberrant signaling in malignancies), and platelet-related diseases.

Validated PLCB2 antibodies typically target epitopes within conserved regions, such as the catalytic X/Y domain or C2 domain, ensuring specificity. Commercial antibodies are often raised in rabbits or mice, with validation data including knockout controls or siRNA knockdowns. Recent studies also explore PLCB2's interaction with G proteins and its modulation by therapeutic agents, highlighting its potential as a biomarker or drug target. Proper antibody selection is crucial, as splice variants and post-translational modifications may affect detection.